Across TCGA pan-cancer cohorts, ICOSLG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ICOSLG data layer compared with 19 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher ICOSLG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ICOSLG expression acts as an unfavorable survival marker.
COAD are the cancer types where ICOSLG Mutation most reproducibly stratifies survival.